• Adult participants ≥ 18 years of age.

• Participants or participant's legally authorized representative has provided informed consent to participate in this study.

• Participants who meet one of the following:

• Prescribed Repatha® in addition to an existing SOC treatment according to local guidelines and approved label.

⁃ OR

• Already received SOC treatment prior to enrollment.

• Participants with ANY of the following.

• Diagnosis of MI OR stroke within 2 years before enrollment.

• 2 MIs OR ≥ 2 strokes OR (≥ 1 MI AND ≥ 1 stroke) any time before enrollment.

• Diagnosis of (MI OR stroke) AND diabetes.

• Diagnosis of (MI OR stroke) AND documented multivessel disease (defined as \> 50% stenosis of ≥ 2 major coronary arteries on coronary angiography or coronary artery contrast enhanced computed tomography).

• Diagnosis of symptomatic peripheral arterial disease.

• Most recent fasting LDL-C ≥ 70 mg/dL (≥ 1.8 mmol/L) or nonhigh-density lipoprotein cholesterol (non-HDL-C) ≥ 100 mg/dL (≥ 2.6 mmol/L) within 6 months prior to enrollment.

• Most recent fasting triglycerides ≤ 400 mg/dL (≤ 4.5 mmol/L) within 6 months prior to enrollment.